Human mumps IgM ELISA kit is intended for analysing in-vitro quantitative concentrations of human IgM antibodies to mumps virus (mumps-IgM) using either plasma or serum. This assay has a minimum analytical sensitivity limit of 1.23 U/ml.
Mumps is a contagious infection that is caused by a virus type which is known as paramyxovirus. It can be passed from one individual to another through nasal secretion, saliva and even close personal contacts. One of the primary signs of mumps is the presence of swollen salivary glands which often causes the cheeks to puff out. In total there are three sets of salivary glands on each side of the face, which are found to be located below and behind the ears. Mumps infection has now become less frequent since the introduction of the measles, mumps and rubella (MMR) vaccine within the UK and many other developed countries. It can however, be found in children that have not yet received the vaccine. Recently, procedures such immunofluorescence, enzyme immunoassay and radio immunoassay have become more popular in detecting mumps in the laboratory.
MUMPS IGM ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Mumps antigen coated microtiter strips.
- Enzyme Conjugate.
- TMB Substrate.
- Sample Diluent.
- Washing Buffer (10x).
- Stop Solution.
- Negative Control (Calibrator A).
- Positive Control (Calibrator D).
- Cut-Off Standard (Calibrator B).
- Weak Positive Control (Calibrator C).
The minimum detection sensitivity level of IgM antibodies to mumps virus (mumps-IgM) using this human mumps IgM ELISA kit was 1.23 U/ml. The dynamic range for this assay is 1.0 – 125.0 U/ml.
– Mumps ELISA: IgM
– Intra-Assay-Precision: 8.7 %
– Inter-Assay-Precision: 6.8 %
– Inter-Lot-Precision: 4.2 – 9.5 %
– Analytical Sensitivity: 1.23 U/mL
– Recovery: 121 – 128 %
– Linearity: 78 – 135 %
– Cross-Reactivity: No cross-reactivity to Measles and Varicella Zoster.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, riglycerides up to 5.0 mg/mL and hemoglobin up to 8.0 mg/mL.
– Clinical Specificity: 75 %
– Clinical Sensitivity: 100 %
- Comparison of automated chemiluminescence immunoassays with capture enzyme immunoassays for the detection of measles and mumps IgM antibodies in serum. J Virol Methods. (2014) 196: 15-7. Haywood B., et al.
- Enzyme-linked immunosorbent assay for mumps IgM antibody: comparison of IgM capture and indirect IgM assay. J Virol Methods. (1985) 12 (3-4): 303-11. Sakata H., et al.
- Comparison of chemiluminescent immunoassay and ELISA for measles IgG and IgM. APMIS. (2015) 123 (8): 648-51. de Ory F., et al.
- Incidence and persistence of mumps-specific IgM and IgA in the sera of mumps patients. Scand J Infect Dis. (1974) 6 (2): 125-9. Bjorvatn B.
- Comparison of mumps IgM ELISAs in acute infection. J Clin Virol. (2007) 38 (2): 153-6. Krause C.H., et al.
- Full Name: Mumps IgM ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: 1.23 U/ml